Round Rock-based Dell reverses remote work policy, mandates in-office presence by March
The announcement comes months after Dell reportedly laid off some employees as part of a focus on artificial intelligence.
Dell is making everyone return to office, too
Technically, Dell had already required its sales, manufacturing, and lab engineers to return to office. The email cites the ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
SchaeffersResearch.com1d
Biotech Stock Rises After FDA Approves Non-Opioid Painkiller
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...
Zacks.com on MSN1d
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate ...
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
BMO raises Vertex stock price target to $545 from $520
BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, moving the goalpost from $520 to $545 while maintaining an Outperform rating. Currently ...